Regent Pacific Group Limited (HKG:0575)
Hong Kong · Delayed Price · Currency is HKD 0.7000
-0.0300 (-4.11%)
Apr 2, 2026, 4:08 PM HKT
Regent Pacific Group Revenue
In the year 2025, Regent Pacific Group had annual revenue of $363.00K USD, down -49.51%. Regent Pacific Group had revenue of $126.00K in the half year ending December 31, 2025, with 1,475.00% growth.
Revenue
$363.00K
Revenue Growth
-49.51%
P/S Ratio
72.30
Revenue / Employee
$21.35K
Employees
17
Market Cap
204.27M HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 363.00K | -356.00K | -49.51% |
| Dec 31, 2024 | 719.00K | 428.00K | 147.08% |
| Dec 31, 2023 | 291.00K | 177.00K | 155.26% |
| Dec 31, 2022 | 114.00K | -3.14M | -96.50% |
| Dec 31, 2021 | 3.25M | 1.58M | 94.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhongzhi Pharmaceutical Holdings | 1.93B |
| Lee's Pharmaceutical Holdings | 1.44B |
| Shenzhen Neptunus Interlong Bio-technique Company | 1.08B |
| Kontafarma China Holdings | 914.71M |
| Wai Yuen Tong Medicine Holdings | 721.27M |
| PuraPharm Corporation | 336.11M |
| Tianda Pharmaceuticals | 322.95M |
| Pak Fah Yeow International | 214.28M |